PhenUtest Diagnostics has completed an extensive rebranding effort as it accelerates towards clinical studies and market readiness. At the heart of this rebrand is the change of name to Innotive Diagnostics (“InnotiveDx”), which ushers in a bold vision of bringing the missing pieces of the diagnostic pathway together in a fast and accurate point of care diagnostic system that can improve antimicrobial stewardship and health equity globally. As part of the rebrand the company has also unveiled a new logo and branding.

Fuelled by a recent round of Series A funding, InnotiveDx is rapidly accelerating development and building towards its entry into the clinic.

“This rebrand is a major milestone for the company and a unique opportunity for the InnotiveDx brand to become synonymous with rapid, accurate, point-of-care, UTI diagnostic testing” said Guy Reynolds, Executive Chairman, adding “This new brand perfectly illustrates our growing ambition in the market.”

InnotiveDx is developing a revolutionary urinary tract infection (UTI) diagnostic system that will diagnose a UTI and provide antimicrobial susceptibility test (AST) results within 60 minutes, providing comprehensive results at the point of care where currently there is none. UTIs are commonly seen in clinical practice and affect hundreds of millions of people per year worldwide, consuming more than 20% of antibiotic prescriptions.

‍